Introduction
============

Multidrug eﬄux pumps are a significant obstacle preventing the control of infections caused by pathogenic bacteria. Genes encoding these transporters have been found in all bacterial genomes sequenced, and the overexpression of just one can lead to the reduced efficacy of a range of structurally and mechanistically unrelated antimicrobials ([@B22]; [@B4]). Five families of transporters that include multidrug eﬄux systems have been studied extensively, and include representative proteins that have been characterized biochemically and by tertiary structural analyses. These include the ATP-binding cassette (ABC) superfamily, the major facilitator superfamily (MFS), the resistance/nodulation/division (RND) superfamily, the small multidrug resistance (SMR) family, and the multidrug and toxic compound extrusion (MATE) family (**Figure [1](#F1){ref-type="fig"}**).

![**Schematic diagram showing the basis for the energisation of multidrug eﬄux pumps operating in bacteria.** The large oval represents the bacterial cell. An electrochemical H^+^ gradient (proton-motive-force) across the cytoplasmic membrane is generated as a result of respiration (green). Energy from the proton-motive-force is used to power transport in secondary active transport systems, such as those within the major facilitator superfamily (MFS), resistance/nodulation/division (RND), and small multidrug resistance (SMR) (super) families. Sodium/proton antiporters (orange) harness the proton-motive-force to generate a Na^+^ gradient that powers transport by other multidrug eﬄux pumps, including those in the multidrug and toxic compound extrusion (MATE) family. ATP production by ATP-synthase (pink) is also powered by the proton-motive-force, and ATP is used to power transport by the primary active transporters of the ATP-binding cassette (ABC) superfamily. Previously characterized eﬄux pump (super) families are shown in red, whereas the proteobacterial antimicrobial compound eﬄux (PACE) family is shown in blue. The PACE family transport proteins are likely to be powered by the H^+^ gradient.](fmicb-06-00333-g001){#F1}

Significant longstanding difficulties surround identifying the physiological functions of these multidrug eﬄux transport proteins and determining which of the many pumps encoded by bacterial strains actually contribute to antimicrobial resistance ([@B20]; [@B24]). Studies have shown that these eﬄux pumps often have overlapping substrate recognition profiles ([@B28]). Furthermore, it is not uncommon for a bacterial genome to encode a large number of eﬄux pumps that have predicted drug substrates, e.g., strains of *Bacillus cereus* encode more than 100 of these pumps accounting for more than 2% or their predicted protein coding potential ([@B22]; [@B27]). It is unlikely that all these pumps share the primary function of protection against toxic compounds, highlighting a need for higher throughput approaches to assess the physiological roles of individual proteins, be they in drug resistance, native housekeeping functions, or other cellular roles.

Eﬄux Pumps Participate in Intrinsic, Adaptive, and Acquired Resistance
======================================================================

Bacterial drug resistance can be divided into three general categories, intrinsic, adaptive, and acquired ([@B7]). Depending on their mode(s) of regulation and their local genetic context, bacterial multidrug eﬄux pumps can be geared to participate in any of these three resistance categories. Intrinsic resistance stems from inherent properties of a bacterial cell and can occur as a result of high constitutive expression and activity of some multidrug eﬄux pumps. Adaptive resistance is related to physiological alterations that are induced by environmental changes and can occur when multidrug eﬄux pumps are expressed in response to antimicrobial substrates. Finally, acquired resistance can result from mutations promoting constitutive expression of an ordinarily tightly controlled endogenous multidrug eﬄux system, or when eﬄux pump genes are acquired on a mobile genetic element, such as a plasmid or phage.

Adaptive Resistance Responses Identify Eﬄux Pumps that Mediate Drug Resistance
==============================================================================

High-level expression of eﬄux pumps can have a negative impact on cell growth ([@B4]), resulting in a need to control the timing of eﬄux system expression to coincide with specific physiological requirements. As such, eﬄux pumps with physiological resistance functions may be characteristically expressed in response to drug substrates. These pumps may be part of an adaptive drug resistance response or part of general stress response regulons. For example, expression of the *adeAB* and *adeIJK* eﬄux pump genes in *Acinetobacter baumannii* ([@B11]; our unpublished data), the *acrAB* and *acrF* genes in *Escherichia coli* ([@B26]; [@B2]), the *mexXY* and *mexCD* genes in *Pseudomonas aeruginosa* ([@B18]), the *norA* gene in *Staphylococcus aureus* ([@B13]), and the *bmr* gene in *Bacillus subtilis* ([@B1]), is induced in response to antimicrobial shock treatments.

The mode of regulation and regulatory cues of most eﬄux pumps are typically only investigated after their functional characterisation. However, global gene expression profiles that show heightened expression of putative eﬄux pump genes following drug or toxin shocks have provided the impetus to assess the drug resistance functions of these pumps. For example, members of our team recognized that an uncharacterised MFS exporter, BC4707, was expressed in response to bile salt shock in the human food-poisoning associated pathogen *Bacillus cereus*, and went on to characterize its role in drug resistance ([@B15]). The gene encoding BC4707 is conserved in the core genome of *B. cereus* and its deletion from *B. cereus* ATCC 14579 resulted in increased susceptibility to norfloxacin ([@B27]). Overexpression of BC4707 in *E. coli* BL21 Δ*acrAB* resulted in increased resistance to norfloxacin, ciprofloxacin, and kanamyacin and fluorescence transport assays showed that accumulation of norfloxacin is reduced by BC4707 in an energy dependent manner ([@B27]).

Adaptive Resistance Responses Identify a New Class of Drug Eﬄux Pump
====================================================================

Extending from this work, we have exploited adaptive resistance responses to identify eﬄux pumps that may mediate drug resistance in hospital-acquired bacterial pathogens, with a focus on biocide resistance. For example, in recent work we conducted a transcriptomic study to examine the regulatory response of *A. baumannii* to a shock treatment with the synthetic biocide chlorhexidine ([@B11]). Chlorhexidine is commonly applied in antibacterial soaps, mouthwashes and antiseptics, and is listed as an "Essential Medicine" by the World Health Organization. Chlorhexidine is a membrane active biocide and as such, multidrug eﬄux pumps are commonly associated with reduced levels of susceptibility ([@B23]; [@B17]). In line with the discussion above, the most highly overexpressed genes in our chlorhexidine shock treatment encoded AdeAB, components of a major tripartite RND multidrug eﬄux system in *A. baumannii* ([@B11]). This eﬄux system has previously been shown to mediate resistance to a very broad range of antimicrobials and biocides, including chlorhexidine ([@B21]). The overexpression of genes encoding AdeAB in response to chlorhexidine confirmed the role of this eﬄux system in adaptive resistance to chlorhexidine in *A. baumannii*. Apart from the genes encoding AdeAB, only one gene was highly (\>10-fold) overexpressed in response to chlorhexidine. This gene was originally annotated as encoding a hypothetical membrane protein. Using biochemical approaches we showed that this protein is in fact a chlorhexidine resistance protein that functions via an active eﬄux mechanism ([@B11]). We named this protein the *[A]{.ul}cinetobacter* [c]{.ul}hlorhexidine [e]{.ul}ﬄux protein I (AceI).

The AceI Transporter is a Prototype for a New Family of Bacterial Multidrug Eﬄux Systems
========================================================================================

The AceI transport protein contains two tandem "Bacterial Transmembrane Pair" (BTP) protein domains defined within the Pfam database ([@B8]). There are more than 750 protein sequences containing this domain architecture listed in the Pfam database (version 27.0). Genes encoding these proteins are particularly common among proteobacterial lineages, but can also be found in the genomes of unrelated bacterial genera, including the Firmicutes and Actinobacteria. We have not yet identified these genes in the genomes of any archaeal or eukaryotic organisms.

We have recently characterized more than 20 homologs of the AceI transporter by heterologous expression in *E. coli* ([@B12]). These studies have demonstrated that many AceI homologs are able to provide resistance to an array of biocides in addition to chlorhexidine. For example, the VP1155 protein from *Vibrio parahaemolyticus* and Bcen2424_2356 protein from *Burkholderia cenocepacia* each conferred increased resistance to chlorhexidine, benzalkonium, acriflavine, and proflavine, when expressed in *E. coli* ([@B12]). Fluorescence transport assays conducted on cells expressing these and other AceI homologs that conferred resistance to acriflavine and proflavine, demonstrated that these compounds are actively exported from the cell by these transporters ([@B12]). These results corroborate our earlier findings that chlorhexidine is actively transported by AceI ([@B11]), and indicate that eﬄux is the mechanism of resistance operating in this group of proteins. Taken together all the observations suggest that these proteins comprise a new family of multidrug eﬄux pumps common amongst Proteobacterial lineages. We have named this family the [P]{.ul}roteobacterial [A]{.ul}ntimicrobial [C]{.ul}ompound [E]{.ul}ﬄux (PACE) family (**Figure [1](#F1){ref-type="fig"}**; [@B12]).

PACE Family Proteins are Encoded Within the Core Genome
=======================================================

Given that the PACE family represents a new class of resistance determinants, we were interested in gathering basic information regarding the mode of inheritance of these genes in bacteria. To this end, we examined their level of conservation within representative bacterial lineages following the basic premise that highly conserved genes within core bacterial genomes are expected to have been inherited vertically, whereas those in the accessory genome are likely to have been horizontally acquired.

We examined PACE family protein conservation in four γ-Proteobacterial species (*A. baumannii*, *P. aeruginosa*, *V. parahaemolyticus,* and *E. coli*) a β-Proteobacterial species (*B. cenocepacia*) and a member of the Firmicutes (*Veillonella parvula*). Annotated protein sequences from all complete and draft genomes of these species were downloaded from the NCBI Genbank database (October, 2014) and were queried using the BTP PfamHMM ([@B8]) in HMMER3 searches ([@B6]). These searches determined that PACE family proteins are encoded in the pan-genomes of all six species examined. To determine the number of distinct orthologous groups of PACE family proteins in each species we performed a clustering analysis based on sequence identity (cluster stringency \>90%) using cd-hit v4.6.1 ([@B9]). This analysis demonstrated that *A. baumannii* had three clusters (100, 96.7, and 0.3% conservation in 623 strains); *P. aeruginosa* had three clusters (99.5, 99.5, and 0.5% conservation in 197 strains); *V. parahaemolyticus* had one cluster (90.1% conservation in 101 strains); *E. coli* had 4 clusters (0.2, 0.1, 0.1, and 0.1% conservation in 1986 strains); *B. cenocepacia* had three clusters (100, 88.9, and 88.9% conservation in nine strains); and *V. parvula* had one cluster (100% conservation in four strains).

These data demonstrate that the pattern of PACE family protein conservation is variable between the species. For example, both *A. baumannii* and *P. aeruginosa* each encode two highly conserved PACE family proteins present in virtually all sequenced strains, and one additional PACE protein encoded in one or two specific strains. Whereas, *V. parahaemolyticus* and *V. parvula* each encode only one highly conserved PACE protein, and *B. cenocepacia* encodes three highly conserved PACE proteins. Most *E. coli* strains do not encode a PACE family protein, although a small handful of strains encode one of four PACE protein variants. The highly conserved PACE family proteins encoded by *A. baumannii*, *P. aeruginosa*, *V. parahaemolyticus*, *B. cenocepacia,* and *V. parvula* are likely to constitute part of the core genome in these species and to have been inherited vertically rather than on mobile genetic elements. The almost complete lack of genes encoding PACE family proteins in *E. coli* strains suggests that these genes were lost early in the development of the *E. coli* lineage, but after its divergence from other γ-proteobacteria. In the few cases where *E. coli* strains were found to encode a PACE family protein, it was sometimes associated with mobile genetic elements suggesting that it had been acquired by horizontal gene transfer. The paucity of PACE genes in *E. coli* strains confirms our previous conclusion that *E. coli* is an excellent host to study the function of these proteins ([@B11]).

Physiological Substrates for PACE Family Transporters
=====================================================

To date, the substrates identified for PACE family transport proteins include synthetic biocides only, such as chlorhexidine, dequalinium, benzalkonium, proflavine, and acriflavine. The presence of these toxic biocides in the environments occupied by Proteobacteria is likely to have been negligible across evolutionary time, until perhaps the last 50--100 years when these compounds were applied in various industries. Given that the organisms encoding PACE family genes are likely to have diverged long before the development of this potential selective pressure, it is seems unlikely that biocides are the native physiological substrates of PACE eﬄux pumps. Nonetheless, these genes are transcriptionally responsive to at least one biocide, chlorhexidine in four species, *A. baumannii*, *A. baylyi*, *P. aeruginosa,* and *B. cenocepacia* ([@B19]; [@B5]; [@B11]), suggesting that chlorhexidine can serve as a mimic of their natural physiological substrate for inducing eﬄux pump expression.

Regulatory Proteins Acting on PACE Eﬄux Pumps
=============================================

In addition to antimicrobial resistance, the promiscuous substrate recognition profiles of multidrug eﬄux pumps allow them to participate in diverse physiological processes. For example, eﬄux systems in Gram-negative bacteria function in cell adherence, invasion, biofilm formation, virulence in animals and plants, and resistance to host encoded factors ([@B20]). Consequently, the regulation of bacterial drug eﬄux systems can be highly complex and responsive to a range of cellular and extracellular conditions. Complex regulation may be particularly apparent in eﬄux pumps, such as AceI and its homologs, which are encoded within core bacterial genomes. These genes are likely to have been present in these species for significant periods of evolutionary time, allowing fine-tuning of their expression in response to a range of environmental cues. A case in point, as summarized within the EcoCyc database ([@B14]), transcription of the *acrAB* eﬄux system genes, within the core genome of *E. coli*, is controlled by at least seven distinct regulatory proteins, which are themselves subject to a range of regulatory pressures. These regulatory proteins are likely to integrate eﬄux pumps into the adaptive resistance responses observed in bacteria, as well as other pathways controlling their alternative physiological functions.

Regulators mediating the most direct control of genes encoding eﬄux pumps are often encoded locally -- adjacent to and divergently transcribed from the gene(s) encoding the eﬄux system. These regulators, either activators or repressors, typically bind a similar spectrum of compounds to their cognate eﬄux pump with high affinity as a signal for transcriptional activation or relief of transcriptional repression. Some well characterized examples include AcrR, which controls transcription of the *E. coli acrAB* eﬄux pump genes ([@B16]), and QacR, which controls *qacA*/*qacB* expression in *S. aureus* ([@B10]; [@B25]).

The PACE family transporters that we have studied to date are each encoded adjacent to a divergently transcribed LysR family regulator. To determine whether these regulators control the expression of their cognate PACE family gene, we used our established methods ([@B4]) to construct a deletion mutant of the regulator gene ACIAD1979 in *A. baylyi* ADP1, which is encoded adjacent to the PACE family chlorhexidine resistance gene ACIAD1978. We examined the expression of ACIAD1978 in both the wild-type and the ΔACIAD1979 regulatory mutant in response to chlorhexidine shock treatments using quantitative real-time PCR analysis ([@B3]). In the absence of chlorhexidine the expression of ACIAD1978 was similar in both strains. However, whereas increasing concentrations of chlorhexidine induced ACIAD1978 gene expression in the wild-type strain, chlorhexidine addition failed to induce ACIAD1978 expression in the ΔACIAD1979 mutant (**Figure [2](#F2){ref-type="fig"}**). These results suggest that the ACIAD1979 LysR family regulator functions as an activator of the PACE family gene ACIAD1978. We are currently investigating the role of LysR family proteins in controlling expression of PACE family pumps in other species and are determining whether the spectrum of ligands recognized by these regulators is closely linked to the substrate recognition profile of their cognate PACE family pump. It also remains to be determined whether the PACE-associated regulators control expression of other genes, or if there are distally encoded regulators that also modulate expression of PACE transporter genes.

![**Expression of the PACE family gene, ACIAD1978, in wild-type and mutant (ΔACIAD1979) *A. baylyi* ADP1 in response to chlorhexidine shock treatments.** Cells were grown in LB broth to OD~600~ = 0.6, then split, with one half of each culture treated with chlorhexidine and the other half receiving no treatment. RNA was isolated and assessed by qRT-PCR following our established protocols ([@B3]) to determine relative expression levels of ACIAD17978 in chlorhexidine treated and untreated samples. Error bars show the SEM. Changes in expression of ACIAD1978 were negligible in the ACIAD1979 mutant treated with 2 mg/L chlorhexidine, and thus the bar is difficult to see.](fmicb-06-00333-g002){#F2}

Conclusion and Future Directions
================================

Transcriptomic analyses of antimicrobial shock treatments are valuable in identifying the potential resistance mechanisms operating in bacteria, including multidrug eﬄux pumps participating in the adaptive resistance response. Using transcriptomic analyses, we have defined roles for new eﬄux pumps and identified the PACE family of multidrug transport proteins, the first new family of drug eﬄux proteins discovered in over a decade.

Transporters within the PACE family are currently enigmas. We have identified drug substrates, such as chlorhexidine that are common to many of these pumps. Furthermore, PACE family gene expression is induced by chlorhexidine, a response that is mediated via locally encoded regulators. This highlights a close relationship between the function of these pumps and their regulatory control. Since PACE family genes are encoded in the core genomes of bacterial lineages that diverged long ago, this functional-regulatory relationship is likely to have arisen early in the evolution of these proteins. However, the substrates/inducers that have been identified for PACE proteins are synthetic biocides that are likely to have been absent from the environment until the last 50--100 years. Therefore, it is unlikely that these biocides would have provided the selective pressure required to drive the functional or regulatory evolution of PACE family pumps. Consequently, a deeper understanding of these novel resistance proteins requires future investigations aimed at identifying their physiological substrate(s) and primary functional roles in bacteria.

The discovery of the PACE family opens up the possibility that there may be more novel eﬄux proteins waiting to be discovered. There are many hypothetical membrane proteins of unknown function encoded in all bacterial genomes. For example, even in the best-studied bacterial genome, *E. coli* K12, there are 409 membrane proteins of unknown function. At least some of these may represent entirely novel types of eﬄux pumps.
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